News

Mounjaro's new heart indication: what SURPASS-CVOT showed, and why it stops at Mounjaro

Q: Did the FDA approve Mounjaro to lower heart risk?

Yes, on August 28, 2026, and only for a specific group. Lilly's release states the FDA approved Mounjaro to lower the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with type 2 diabetes who are at high risk for these events. The evidence is SURPASS-CVOT, which compared tirzepatide with Trulicity (dulaglutide) 1.5 mg rather than with placebo, and which met non-inferiority. As of September 2, 2026 the Mounjaro Structured Product Label on DailyMed, version 38, had not yet been revised to carry the new indication.

Q: Does this mean Mounjaro protects the heart better than the alternatives?

No. SURPASS-CVOT was a non-inferiority trial against an active comparator that already had a cardiovascular benefit. A first MACE-3 event occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group, hazard ratio 0.92 with a 95.3% confidence interval of 0.83 to 1.01. Because that interval crosses 1, superiority was not established; the paper reports P equals 0.09 for superiority, and Lilly's release states that superiority to dulaglutide was not established. The result rules out meaningful inferiority to a drug that works. It does not rank tirzepatide above it.

Q: Does the new indication apply to Zepbound?

No. Mounjaro and Zepbound are the same molecule, tirzepatide, sold by Eli Lilly under two brand names with two separate labels. Indications attach to a product's labelling, not to a molecule. The current Zepbound label, SPL version 38 published May 6, 2026, is indicated only to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight plus a weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. It carries no cardiovascular indication.

Q: Which has cardiovascular outcome evidence for someone taking a GLP-1 for weight, tirzepatide or semaglutide?

Semaglutide, and only within a defined group. SELECT randomised 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes to semaglutide 2.4 mg or placebo; a first MACE-3 event occurred in 6.5% versus 8.0%, hazard ratio 0.80 with a 95% confidence interval of 0.72 to 0.90. That result is on the Wegovy label as its first indication, limited to adults with established cardiovascular disease and either obesity or overweight. Tirzepatide has no equivalent result in a weight-management population yet. SURMOUNT-MMO, which randomised 15,374 adults with a BMI of at least 27 and without diabetes against placebo, has an estimated primary completion of October 2027.

Q: Why does a non-inferiority trial count for approval at all?

Because in a population that already has an effective treatment, withholding it to run a placebo arm raises an ethical problem, so regulators accept a comparison against an active agent with a prespecified margin. SURPASS-CVOT set that margin at 1.05 for the upper limit of the 95.3% confidence interval. The design is not the weakness; the comparator and the interval are what determine what can be claimed. Ozempic's SUSTAIN 6 was also a non-inferiority trial, with a margin of 1.3, but it was run against placebo and its hazard ratio of 0.74, 95% confidence interval 0.58 to 0.95, excluded 1, so a reduction was demonstrated.

By the US Health Digest editorial team · Published September 2, 2026 · Every claim linked to its primary source

On August 28, 2026 the FDA approved Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for them, Eli Lilly announced. The trial behind it, SURPASS-CVOT, randomised 13,299 adults against Trulicity (dulaglutide) 1.5 mg — not placebo. A first MACE-3 event occurred in 12.2% on tirzepatide and 13.1% on dulaglutide: hazard ratio 0.92, 95.3% CI 0.83 to 1.01. The interval crosses 1. Non-inferiority was met; superiority was not. And the indication sits on Mounjaro, not on Zepbound.

This page reports what regulatory documents and published trials say. It is not advice to start, stop or change any medicine.

What the FDA approved, in the approval's own terms

Lilly's August 28, 2026 release states that the FDA approved Mounjaro, a dual GIP and GLP-1 receptor agonist, to lower the risk of major adverse cardiovascular events including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health, is quoted in that release saying Mounjaro now gives people with type 2 diabetes “a proven way to lower that risk, adding to the strong foundation it has already built in A1C and weight”.

Two boundaries are already visible in that sentence. The population is adults with type 2 diabetes who are at high cardiovascular risk. And the brand is Mounjaro — Lilly's type 2 diabetes product — not Zepbound, the same molecule sold for weight management.

SURPASS-CVOT was an active-comparator non-inferiority trial

The trial report is Nicholls et al., New England Journal of Medicine, December 18, 2025 (NCT04255433). One disclosure before the numbers: the NEJM full text is behind a paywall we could not reach, so every SURPASS-CVOT figure and quotation on this page comes from the structured abstract indexed in PubMed. We have not read the full paper, its supplement or its protocol.

The design is the whole story. Participants had type 2 diabetes and atherosclerotic cardiovascular disease, and were randomised 1:1 to tirzepatide (up to 15 mg) or dulaglutide 1.5 mg — described in that abstract as “an agent that has been shown to reduce the incidence of cardiovascular events”. The primary endpoint was tested for non-inferiority “with a margin of 1.05 for the upper limit of the 95.3% confidence interval for the hazard ratio”, and the abstract states that “An upper limit of less than 1.00 was considered to indicate superiority of tirzepatide to dulaglutide.”

Of 13,299 randomised, 134 were excluded for not meeting inclusion criteria, leaving a modified intention-to-treat population of 6,586 on tirzepatide and 6,579 on dulaglutide. Mean age was 64.1 years, mean HbA1c 8.4%, mean diabetes duration 14.7 years, and 29.0% were women. A primary event occurred in 801 patients (12.2%) on tirzepatide and 862 (13.1%) on dulaglutide: hazard ratio 0.92, 95.3% CI 0.83 to 1.01, P = 0.003 for non-inferiority and P = 0.09 for superiority. Lilly's release adds that median follow-up was 210.1 weeks and states plainly that “Superiority to dulaglutide was not established.”

So the honest reading of the shorthand Mounjaro cuts heart risk is narrower than the phrase sounds: over roughly four years, tirzepatide produced 0.9 percentage points fewer first MACE-3 events than an older Lilly drug that already carried the benefit, and the confidence interval around that difference includes no difference at all. That is a legitimate regulatory result — ruling out meaningful inferiority to an active agent is what the trial was built to do. It is not the same claim as being better than the alternative.

The trial's investigators did publish an estimate of the placebo comparison the trial never ran. A prespecified exploratory analysis in Diabetes Care multiplied the SURPASS-CVOT hazard ratio by the dulaglutide-versus-placebo hazard ratio from REWIND, using 2,055 propensity-matched REWIND participants, and reported an imputed tirzepatide-versus-placebo MACE-3 hazard ratio of 0.72 (95% CI 0.55 to 0.94). That is an indirect, cross-trial construction, not a randomised comparison, and its own authors label it exploratory. A separate editorial in the Journal of the American College of Cardiology is titled “On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT.”

What the labels actually said on September 2, 2026

We read section 1, Indications and Usage, of five current Structured Product Labels on DailyMed on September 2, 2026. DailyMed is the canonical source for current US labelling; company PDFs and press releases can run ahead of it.

Mounjaro — SPL version 38, published May 6, 2026, document effective April 22, 2026, printed "Revised: 4/2026". Section 1 reads, in full: MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The new cardiovascular indication is not on it yet. The strings "MACE", "major adverse", "cardiovascular outcome", "SURPASS-CVOT" and "dulaglutide" appear zero times in the document; the two occurrences of "cardiovascular" are both in the SURPASS-4 description in section 14.
Zepbound — SPL version 38, published May 6, 2026, effective April 22, 2026. Same molecule, same manufacturer, different label. It is indicated with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight plus a weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. No cardiovascular indication.
Wegovy — SPL version 19, published June 30, 2026. Its first indication bullet, for both the injection and the tablets, is to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
Ozempic (SPL version 20) and Trulicity (SPL version 62) both already carry MACE-reduction indications in type 2 diabetes.

A label lagging its approval by days is ordinary. We are reporting the gap rather than papering over it: as of the date above, the document a pharmacist or prescriber pulls up for Mounjaro does not yet describe the indication the FDA granted on August 28.

Tirzepatide versus semaglutide on cardiovascular evidence

Cardiovascular outcome evidence behind five US GLP-1 and dual-agonist labels. Trial figures from the primary publications and from the Clinical Studies sections of the labels themselves; label wording from DailyMed. Retrieved September 2, 2026.
Product (molecule)	Trial	Comparator	Randomised	Follow-up	Primary endpoint	Result	What the current label says
Mounjaro (tirzepatide)	SURPASS-CVOT (NCT04255433)	Dulaglutide 1.5 mg (active)	13,299 (13,165 modified ITT)	Median 210.1 weeks	MACE-3; non-inferiority, margin 1.05 on the upper 95.3% CI	12.2% vs 13.1%; HR 0.92 (95.3% CI 0.83–1.01). Non-inferiority met; superiority not established	SPL v38, effective April 22, 2026: glycemic control only. FDA approved the CV indication August 28, 2026; the SPL had not been revised as of September 2, 2026
Zepbound (tirzepatide)	SURMOUNT-MMO (NCT05556512)	Placebo	15,374 (actual)	Up to 5 years; primary completion estimated October 2027	Composite of all-cause death, non-fatal MI, non-fatal stroke, coronary revascularisation or heart failure events	No results. Active, not recruiting	SPL v38: weight management and obstructive sleep apnea. No CV indication
Wegovy (semaglutide 2.4 mg)	SELECT (NCT03574597)	Placebo	17,604	Mean 39.8 months (label: median 41.8 months)	MACE-3; event-driven superiority	6.5% vs 8.0%; HR 0.80 (95% CI 0.72–0.90), P<0.001	SPL v19: first indication is MACE reduction in adults with established CV disease and either obesity or overweight
Ozempic (semaglutide)	SUSTAIN 6 (NCT01720446)	Placebo	3,297	Median 2.1 years	MACE-3; non-inferiority, margin 1.3	HR 0.74 (95% CI 0.58–0.95) — interval excludes 1	SPL v20: MACE reduction in type 2 diabetes with established CV disease, plus a kidney indication
Trulicity (dulaglutide)	REWIND (NCT01394952)	Placebo	9,901	Median 5.4 years	MACE-3	12.0% vs 13.4%; HR 0.88 (95% CI 0.79–0.99)	SPL v62: MACE reduction in type 2 diabetes with established CV disease or multiple CV risk factors

The Ozempic row is worth a second look, because it defeats the lazy version of this story. SUSTAIN 6 was also designed as a non-inferiority trial. The difference is not the design label; it is the comparator and the interval. SUSTAIN 6 tested semaglutide against placebo and its confidence interval excluded 1, so a reduction was demonstrated. SURPASS-CVOT tested tirzepatide against a drug that already worked, and its interval did not exclude 1.

Bars are drawn at exactly 30 px per percentage point from a shared zero at x=210. The chart is not a cross-trial comparison: the three populations, durations and background therapies differ, and only the two bars inside each pair were randomised against one another. What it does show is structural — in SURPASS-CVOT both bars are an active drug, so the gap between them is not the drug's effect on untreated risk.

Why the indication does not reach Zepbound

Mounjaro and Zepbound are the same molecule, tirzepatide, marketed by Eli Lilly under two brand names with two separate labels and two separate sets of indications. US indications attach to an application and its labelling, not to a molecule, which is why the Zepbound label carries obstructive sleep apnea and the Mounjaro label does not, and why neither Mounjaro nor Ozempic carries a weight-management indication. An indication granted for Mounjaro in type 2 diabetes does not migrate to Zepbound.

The population matters as much as the brand. SURPASS-CVOT required type 2 diabetes and established atherosclerotic cardiovascular disease; mean HbA1c at entry was 8.4% and mean diabetes duration was nearly 15 years. Most readers taking tirzepatide for weight are taking Zepbound and do not have type 2 diabetes. Nothing in this approval speaks to them.

The trial that will is SURMOUNT-MMO: 15,374 adults aged 40 and over with a BMI of at least 27, randomised against placebo, with type 1 and type 2 diabetes among the exclusion criteria. Its primary outcome is time to first occurrence of all-cause death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation or a heart failure event. The registry record lists it as active and not recruiting, with primary completion estimated for October 2027.

What this does and does not change

It changes: tirzepatide now has a randomised cardiovascular outcome trial with a published NEJM report and, per Lilly, an FDA indication in type 2 diabetes at high cardiovascular risk. Before August 28 it had neither. Our GLP-1 statistics page should be read with that addition in mind.

It does not change: what any label says about weight management. It does not establish that tirzepatide reduces cardiovascular events more than dulaglutide, semaglutide or any other agent — no such superiority test succeeded, and we found no randomised head-to-head of tirzepatide against semaglutide on cardiovascular outcomes, either published or registered. It does not give Zepbound a cardiovascular indication. And it does not answer the question a woman without diabetes and without established heart disease is actually asking, because neither molecule has an outcome indication for her: Wegovy's requires established cardiovascular disease, and Mounjaro's requires type 2 diabetes. Our Wegovy versus Zepbound comparison and our note on how these trials enrol women both sit under that limit — SURPASS-CVOT was 29.0% women and SELECT was 72% male.

Questions this raises for a prescriber

Which product am I actually prescribed — Mounjaro or Zepbound — and which indication on that product's label applies to me?
Do I meet the population the cardiovascular evidence came from: type 2 diabetes with established atherosclerotic disease, or overweight with established cardiovascular disease?
If cardiovascular risk is the reason for treatment, which available drug has placebo-controlled outcome data in a population resembling mine?
Has the Mounjaro prescribing information been revised since August 28, 2026, and what does its section 1 say now?

Frequently asked questions

Did the FDA approve Mounjaro to lower heart risk?

Yes, on August 28, 2026, and only for a specific group. Lilly's release states the FDA approved Mounjaro to lower the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with type 2 diabetes who are at high risk for these events. The evidence is SURPASS-CVOT, which compared tirzepatide with Trulicity (dulaglutide) 1.5 mg rather than with placebo, and which met non-inferiority. As of September 2, 2026 the Mounjaro Structured Product Label on DailyMed, version 38, had not yet been revised to carry the new indication.

Does this mean Mounjaro protects the heart better than the alternatives?

No. SURPASS-CVOT was a non-inferiority trial against an active comparator that already had a cardiovascular benefit. A first MACE-3 event occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group, hazard ratio 0.92 with a 95.3% confidence interval of 0.83 to 1.01. Because that interval crosses 1, superiority was not established; the paper reports P equals 0.09 for superiority, and Lilly's release states that superiority to dulaglutide was not established. The result rules out meaningful inferiority to a drug that works. It does not rank tirzepatide above it.

Does the new indication apply to Zepbound?

No. Mounjaro and Zepbound are the same molecule, tirzepatide, sold by Eli Lilly under two brand names with two separate labels. Indications attach to a product's labelling, not to a molecule. The current Zepbound label, SPL version 38 published May 6, 2026, is indicated only to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight plus a weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. It carries no cardiovascular indication.

Which has cardiovascular outcome evidence for someone taking a GLP-1 for weight, tirzepatide or semaglutide?

Semaglutide, and only within a defined group. SELECT randomised 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes to semaglutide 2.4 mg or placebo; a first MACE-3 event occurred in 6.5% versus 8.0%, hazard ratio 0.80 with a 95% confidence interval of 0.72 to 0.90. That result is on the Wegovy label as its first indication, limited to adults with established cardiovascular disease and either obesity or overweight. Tirzepatide has no equivalent result in a weight-management population yet. SURMOUNT-MMO, which randomised 15,374 adults with a BMI of at least 27 and without diabetes against placebo, has an estimated primary completion of October 2027.

Why does a non-inferiority trial count for approval at all?

Because in a population that already has an effective treatment, withholding it to run a placebo arm raises an ethical problem, so regulators accept a comparison against an active agent with a prespecified margin. SURPASS-CVOT set that margin at 1.05 for the upper limit of the 95.3% confidence interval. The design is not the weakness; the comparator and the interval are what determine what can be claimed. Ozempic's SUSTAIN 6 was also a non-inferiority trial, with a margin of 1.3, but it was run against placebo and its hazard ratio of 0.74, 95% confidence interval 0.58 to 0.95, excluded 1, so a reduction was demonstrated.

Sources

Eli Lilly and Company. FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. August 28, 2026. Indication wording, 13,299 participants across 640 sites in 30 countries, median follow-up 210.1 weeks, hazard ratio 0.92 (95.3% CI 0.83, 1.01), and the statement that superiority to dulaglutide was not established.
Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409–2420. PMID 41406444. Registered as NCT04255433.
Sattar N, Gerstein HC, D'Alessio D, et al. Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND. Diabetes Care. 2026. PMID 41940793.
Kaul S. On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT. J Am Coll Cardiol. 2026;87(21):3029–3031. PMID 42233554.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. PMID 37952131. Registered as NCT03574597.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394(10193):121–130. PMID 31189511. Registered as NCT01394952.
DailyMed. MOUNJARO (tirzepatide) injection — current prescribing information. SPL version 38, published May 6, 2026; document effective April 22, 2026. Section 1 and section 14.
DailyMed. ZEPBOUND (tirzepatide) injection. SPL version 38, published May 6, 2026; effective April 22, 2026. Section 1.
DailyMed. WEGOVY (semaglutide) injection and tablets. SPL version 19, published June 30, 2026; effective June 18, 2026. Sections 1 and 14.1.
DailyMed. OZEMPIC (semaglutide) injection. SPL version 20, published June 10, 2026; effective June 1, 2026. Sections 1 and 14, SUSTAIN 6.
DailyMed. TRULICITY (dulaglutide) injection. SPL version 62, published August 10, 2026; effective June 16, 2026. Section 1.
ClinicalTrials.gov. SURMOUNT-MMO (NCT05556512), tirzepatide versus placebo on morbidity and mortality in adults with obesity; actual enrolment 15,374; active, not recruiting; estimated primary completion October 2027. Record retrieved September 2, 2026.

This article is for information only and is not medical advice. Prescription weight-loss medication requires evaluation by a licensed clinician. See our medical disclaimer.